XLO XILIO THERAPEUTICS INC Earnings Reports 8-K Filing 2024 - Q3 2024 Results Xilio Therapeutics, Inc. announced its financial results for Q3 2024 and initial data from a clinical trial for vilastobart (XTX101) in combination with atezolizumab, presented at a major cancer meeting.Get access to all SEC 8-K filings of the XILIO THERAPEUTICS INC